Podcasts about advanced breast cancer

  • 61PODCASTS
  • 117EPISODES
  • 22mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • May 29, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about advanced breast cancer

Latest podcast episodes about advanced breast cancer

CCO Oncology Podcast
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

CCO Oncology Podcast

Play Episode Listen Later May 29, 2025 35:15


In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:Key Comorbidities in Patients with HR+/HER2- MBCImpact of PolypharmacyRole of APPs in Comprehensive CareRole of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBCUtility of RWE dataCommunicating Treatment Options With Patients and CaregiversUnderstanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of LifeLink to full program:https://bit.ly/4jCQe38

The Burn
For Now is As Good As Forever: Dating with Advanced Breast Cancer with Deltra James (Explicit)

The Burn

Play Episode Listen Later Apr 30, 2025 30:23


Deltra James was diagnosed at 33 with de novo Stage IV, Triple Negative MBC. She is a New England based mama, poet, patient advocate, and co-host of the Empowered Intimacy podcast. In this episode Deltra reads her piece “For Now is As Good As Forever: Dating with Advanced Breast Cancer” from the 2024 “MBC: Advocacy” issue of Wildfire Journal. Her essay is about one woman's experience of dating alongside her metastatic breast cancer diagnosis, and podcasting about it. April and Deltra will discuss being open to sharing cancer stories, cancer's impact on established relationship vows, dating new people after cancer, and empowered intimacy challenges after cancer. This episode contains sexual content.More about Deltra:https://www.instagram.com/deltra_does_it/https://youtube.com/playlist?list=PLQqB9UtXWxPio1JOyDBTn-sA4TIuPRa2o&si=kIXAwVFtnG6mXD7FMore about our episode sponsor Rethink Breast Cancer:https://www.instagram.com/rethinkbreastcancer/https://rethinkbreastcancer.com/find-community?utm_campaign=featured_banner_THERETHINKNETWORK&utm_medium=referral&utm_source=later-linkinbioPurchase the “MBC: Advocacy” issue of Wildfire Magazine: https://www.wildfirecommunity.org/shop/p/family24Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860Get the free Wildfire “Hot Flashes” email newsletter: https://www.wildfirecommunity.org/newsletter?rq=newsletterLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shop*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeMore about Wildfire Magazine: https://www.wildfirecommunity.orghttps://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunityInformation on submitting your story for consideration to be published in Wildfire Magazine: https://www.wildfirecommunity.org/submissions

ProCE: The Pharmacy Practice Podcast
How Pharmacists Can Enhance Comprehensive Patient-Centered Care for Patients With HR+/HER2- MBC and Comorbidities

ProCE: The Pharmacy Practice Podcast

Play Episode Listen Later Apr 29, 2025 16:41


In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

CCO Oncology Podcast
How Pharmacists Can Enhance Comprehensive Patient-Centered Care for Patients With HR+/HER2- MBC and Comorbidities

CCO Oncology Podcast

Play Episode Listen Later Apr 25, 2025 16:41


In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

CME in Minutes: Education in Primary Care
Aditya Bardia, MD / Sara Hurvitz, MD - Making a World of Difference for Patients With HER2-Low and -Ultralow Advanced Breast Cancer: Practical Strategies to Integrate Antibody-Drug Conjugates in Special Populations

CME in Minutes: Education in Primary Care

Play Episode Listen Later Apr 16, 2025 30:09


Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

CME in Minutes: Education in Primary Care
Aditya Bardia, MD / Sara Hurvitz, MD - Realizing the Potential of Antibody-Drug Conjugates in HER2-Low and -Ultralow Advanced Breast Cancer: Evolving Strategies to Individualize Care

CME in Minutes: Education in Primary Care

Play Episode Listen Later Apr 10, 2025 26:25


Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

CME in Minutes: Education in Primary Care
Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer

CME in Minutes: Education in Primary Care

Play Episode Listen Later Apr 4, 2025 21:51


Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,

PeerVoice Oncology & Haematology Video
Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Mar 19, 2025 20:04


Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

PeerVoice Clinical Pharmacology Video
Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

PeerVoice Clinical Pharmacology Video

Play Episode Listen Later Mar 19, 2025 20:04


Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

Radiology Podcasts | RSNA
Screening Gaps and the Rise in Advanced Breast Cancer

Radiology Podcasts | RSNA

Play Episode Listen Later Mar 18, 2025 27:55


Dr. Reni Butler speaks with Dr. Ed Hendrick and Dr. Debbie Monticciolo about the rising rates of metastatic breast cancer and the vital role of early detection through screening. They discuss their latest research, the impact of screening guidelines, and the urgent need to improve access and participation in breast cancer screening. Surveillance, Epidemiology, and End Results Data Show Increasing Rates of Distant-Stage Breast Cancer at Presentation in U.S. Women. Hendrick and Monticciolo. Radiology 2024; 313(3):e241397.  

Pharma and BioTech Daily
Pharma and Biotech Daily: FDA Approves New Treatments and Collaborations in the Industry

Pharma and BioTech Daily

Play Episode Listen Later Feb 24, 2025 3:09


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Title: Pfizer and BioNTech seek FDA approval for COVID-19 vaccine boosterPfizer and BioNTech have announced that they are seeking authorization from the FDA for a booster dose of their COVID-19 vaccine. The companies have presented data showing that a third dose of the vaccine can significantly increase protection against the Delta variant.##Title: Moderna to supply 100 million more doses of COVID-19 vaccine to the USModerna has reached an agreement with the US government to supply an additional 100 million doses of its COVID-19 vaccine. The company will deliver the doses by the end of the year, helping to boost vaccination efforts across the country.##Title: AstraZeneca's COVID-19 antibody treatment shows promising results in clinical trialsAstraZeneca has announced that its COVID-19 antibody treatment has shown promising results in clinical trials. The treatment, which is designed to prevent severe disease and hospitalization, could provide an important new tool in the fight against the virus.##Title: Novartis receives FDA approval for new treatment for advanced breast cancerNovartis has received FDA approval for a new treatment for advanced breast cancer. The drug, which targets a specific genetic mutation, has been shown to significantly improve progression-free survival in patients with the disease.##Title: Roche announces positive results from phase 3 trial of Alzheimer's drugRoche has announced positive results from a phase 3 trial of its Alzheimer's drug. The drug, which is designed to target the underlying cause of the disease, showed significant improvement in cognitive function and daily living activities in patients with early-stage Alzheimer's.##Title: Johnson & Johnson to invest $6.5 billion in expanding vaccine production capacityJohnson & Johnson has announced plans to invest $6.5 billion in expanding its vaccine production capacity. The company aims to increase production of its COVID-19 vaccine as well as other vaccines in its portfolio, helping to address global supply shortages.##Title: Merck receives FDA approval for new treatment for certain types of lung cancerMerck has received FDA approval for a new treatment for certain types of lung cancer. The drug, which targets a specific genetic mutation, has been shown to improve overall survival in patients with advanced disease.##Title: Gilead Sciences announces collaboration with Novartis on HIV researchGilead Sciences has announced a collaboration with Novartis on HIV research. The companies will work together to develop new treatments for HIV, with a focus on addressing drug resistance and improving outcomes for patients with the virus.## Title: Eli Lilly receives FDA approval for new treatment for migraineEli Lilly has received FDA approval for a new treatment for migraine. The drug, which is administered through an injection, has been shown to provide rapid relief from migraine symptoms and reduce the frequency of attacks in patients with the condition.

Keeping Current
Shaping the Future of Advanced Breast Cancer Care: A Deep Dive Into Novel Data and Emerging Therapies

Keeping Current

Play Episode Listen Later Jan 29, 2025 29:37


Did you know that estrogen receptor-targeting therapies could help reduce chemotherapy exposure and its associated toxicities in advanced HER2-positive disease?   Credit available for this activity expires: 1/29/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002178?ecd=bdc_podcast_libsyn_mscpedu

CCO Oncology Podcast
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

CCO Oncology Podcast

Play Episode Listen Later Jan 9, 2025 36:04


In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:Estrogen Receptor Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerCurrent Guideline Recommendations for When to Pursue ESR1 Mutation Testing Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerChoice and Sequencing of Next Line of Systemic Therapy for ESR1-Mutated Advanced Breast Cancer Based on Tumor Molecular AlterationsOverview of Class-Related and Unique Adverse Events With Approved and Emerging Oral SERDSExpert Recommendations for the Management of Oral SERDs-Related Adverse EventsProgram faculty:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchDana-Farber Cancer InstituteAssociate Professor in MedicineHarvard Medical SchoolBoston, MassachusettsLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To download the slides associated with this podcast discussion, please visit the program page.

Oncology Brothers
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer

Oncology Brothers

Play Episode Listen Later Nov 25, 2024 23:24


Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study. Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations. Key topics discussed include: •⁠  ⁠Overview of the INAVO120 study and its significance •⁠  ⁠The unique patient population targeted in the study •⁠  ⁠Key findings, including the impressive improvement in progression-free survival (PFS) •⁠  ⁠Side effects and management strategies for patients •⁠  ⁠The importance of genetic testing in treatment decisions Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Pharmacy Focus
S2 Ep39: Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Pharmacy Focus

Play Episode Listen Later Oct 28, 2024 11:52


Expert discussed the potential of pelareorep, a novel immunotherapeutic agent, in treating advanced or metastatic breast cancer, particularly in HR-positive, HER2-negative patients, and the plans for further clinical development of pelareorep in this indication.

Curing with Sound
Ep16: Treating Advanced Breast Cancer with Noninvasive Focused Ultrasound and Radiation: A Conversation with Dr. Gregory Czarnota

Curing with Sound

Play Episode Listen Later Oct 24, 2024 28:00


In recognition of Breast Cancer Awareness Month, Dr. Greg Czarnota, a senior scientist and radiation oncologist at Sunnybrook Research Institute in Toronto, discusses his innovative research using focused ultrasound in breast cancer treatment. Dr. Czarnota shares promising results from his phase I clinical trial using focused ultrasound-stimulated microbubbles to enhance radiotherapy in patients with advanced breast cancers. Key points from the conversation include: The origins of Dr. Czarnota's interest in focused ultrasound and its application in enhancing radiotherapy. He shares details of the upcoming phase II clinical trials that will be enrolling patients with inoperable breast cancer. Technical advances with the Arrayus focused ultrasound device could treat larger and more complex tumors. Dr. Czarnota has also developed ultrasound imaging methods to detect cell death. SHOW TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/  

Targeted Talks
S5 Ep17: Kaklamani's Insights on EMERALD Trial and Elacestrant in Advanced Breast Cancer

Targeted Talks

Play Episode Listen Later Sep 26, 2024 13:41


In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio and the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses the background, findings, and implications of the phase 3 EMERALD trial.

Research To Practice | Oncology Videos
Breast Cancer | Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 29, 2024 75:44


Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57) Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59) Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42) Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55) Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12) CME information and select publications

CME in Minutes: Education in Primary Care
Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer

CME in Minutes: Education in Primary Care

Play Episode Listen Later Aug 9, 2024 18:36


Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.

Podcasts from the Cochrane Library
Do bone-modifying medicines help reduce bone loss in women with early or locally advanced breast cancer?

Podcasts from the Cochrane Library

Play Episode Listen Later Aug 6, 2024 4:41


Cochrane has produced several systematic reviews that assess the potential benefits and harms of medicine that might help to prevent bone loss in people with breast cancer. In this podcast, Claire Iannizzi talks with lead author Anne Adams, both from the University Hospital Cologne in Germany, about a review of different bone-modifying agents for reducing bone loss in women with non-metastatic breast cancer, which was published for the first time in July 2024.

Podcasts from the Cochrane Library
Do bone-modifying medicines help reduce bone loss in women with early or locally advanced breast cancer?

Podcasts from the Cochrane Library

Play Episode Listen Later Aug 6, 2024 4:41


Cochrane has produced several systematic reviews that assess the potential benefits and harms of medicine that might help to prevent bone loss in people with breast cancer. In this podcast, Claire Iannizzi talks with lead author Anne Adams, both from the University Hospital Cologne in Germany, about a review of different bone-modifying agents for reducing bone loss in women with non-metastatic breast cancer, which was published for the first time in July 2024.

CCO Oncology Podcast
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

CCO Oncology Podcast

Play Episode Listen Later Jul 22, 2024 34:45


In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.Presenters:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasAditya Bardia, MD, MPH, FASCOProfessor of MedicineGeffen School of Medicine at UCLADirector, Breast Oncology ProgramAssistant Chief (Translational Research)Division of Medical OncologyDirector of Translational Research IntegrationUCLA Health Jonsson Comprehensive Cancer CenterLos Angeles, CaliforniaSarah Sammons, MDAssistant Professor of MedicineDana-Farber Cancer Institute Harvard Medical SchoolBoston, Massachusetts Link to full program:https://bit.ly/46hLGcM

CCO Oncology Podcast
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

CCO Oncology Podcast

Play Episode Listen Later Jul 9, 2024 24:30


In this episode, Dr Joyce O'Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancerFactors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expressionDetermining the need for adjuvant chemotherapy and selection of chemotherapy agentsSelection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapyPotential use of preoperative CDK4/6 inhibitorsSequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutationOverview of first-line therapy for advanced HR+/HER2 breast cancerExpert opinion on selection of first-line therapy and factors to considerSelection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trialPresenters:Joyce O'Shaughnessy, MDCelebrating Women Chair in Breast Cancer ResearchBaylor University Medical CenterChair, Breast Disease CommitteeSarah Cannon Research InstituteTexas OncologyDallas, TexasSara A. Hurvitz, MD, FACPProfessor of MedicineHead, Division of Hematology and OncologyDepartment of Medicine, UW MedicineSenior Vice PresidentClinical Research DivisionFred Hutchinson Cancer CenterSeattle, WashingtonErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchInstitute PhysicianDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program: https://bit.ly/3XZKp8f

PeerVoice Clinical Pharmacology Audio
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Clinical Pharmacology Audio

Play Episode Listen Later May 10, 2024 21:39


Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Oncology & Haematology Video
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Oncology & Haematology Video

Play Episode Listen Later May 10, 2024 26:50


Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Oncology & Haematology Audio
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Oncology & Haematology Audio

Play Episode Listen Later May 10, 2024 21:39


Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Internal Medicine Audio
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Internal Medicine Audio

Play Episode Listen Later May 10, 2024 21:39


Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Clinical Pharmacology Video
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Clinical Pharmacology Video

Play Episode Listen Later May 10, 2024 26:50


Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Internal Medicine Video
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

PeerVoice Internal Medicine Video

Play Episode Listen Later May 10, 2024 26:50


Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Oncology for the Inquisitive Mind
97. Spotlight: Advanced Breast Cancer - Which CDK4/6 Inhibitor is Best?

Oncology for the Inquisitive Mind

Play Episode Listen Later Apr 6, 2024 25:46


It is a tale as old as time, as old as the stars, the heavens and human consciousness itself. Okay, we're exaggerating a bit, but for as long as pharmacology and capitalism have been joined at the hip, the question of "which drug is best" has been at or near the forefront of medical decision-making. With the development of standardised clinical trials and the difficulty of conducting direct head-to-head comparisons, this question has become more difficult to answer conclusively. Nowhere is this epitomised better than with the triptych of available CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib. A lot of ink and pixels have been devoted to comparing the pivotal trials of these three equally pivotal agents: PALOMA-2, MONALEESA-2 and MONARCH-3, respectively. However, Josh and Michael have brought the definitive and not-at-all rambling answer to this question. Listen on to find out!Links to studies discussed in this episode (subscription may be required):Review Article (Grinshpun et al.): https://www.nature.com/articles/s41523-023-00520-7For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Our MBC Life
S08 E02 Report Back From SABCS 2023: Spotlight on the Latest in MBC

Our MBC Life

Play Episode Listen Later Mar 20, 2024 52:48


Today we are bringing you a special episode that we created in partnership with SHARE Cancer Support. It's an audio version of a live webinar that was done this past February called Report back from San Antonio Breast Cancer Symposium 2023. SABCS is the world's leading breast cancer research meeting where scientists, patient advocates, and others dedicated to working in the field of cancer gather.In this podcast, Dr. Timothy Pluard, director of the Saint Luke's Koontz Center for Advanced Breast Cancer, breaks down the promising research, targeted therapy, the evolving treatment after CDK 4/6 inhibitors, liquid biopsy and more.

CCO Oncology Podcast
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer

CCO Oncology Podcast

Play Episode Listen Later Mar 18, 2024 36:29


In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:Challenges with the pathologic testing for HER2-low expressionOptimal treatment of patients with HER2-low advanced breast cancerRole of TROP-2–targeted therapiesManagement of ADC-associated adverse events to optimize treatment outcomesADCs on the horizon for patients with advanced breast cancerPresenters:Sara M. Tolaney, MD, MPHChief, Division of Breast OncologyDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsMelinda Telli, MDProfessor of MedicineStanford University School of MedicineDirector, Breast Cancer ProgramStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.Link to full program:https://bit.ly/49WxRBM

At The Beam
S2E13 Locally Advanced Breast Cancer feat. Dr Alexandra Bennett

At The Beam

Play Episode Listen Later Jan 5, 2024 18:33


Case-based workup and management of another locally advanced breast cancer case in radiation oncology. Featuring guest Dr Alexandra Bennett.

Oncology Data Advisor
Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN

Oncology Data Advisor

Play Episode Listen Later Nov 2, 2023 14:34


For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.

Oncotarget
Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

Oncotarget

Play Episode Listen Later Sep 13, 2023 2:52


A new editorial paper was published in Oncotarget's Volume 14 on July 7, 2023, entitled, “Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?” In their new editorial, researchers Marta Vaz Batista, José Perez-Gracia, Inês Eiriz, Maria Gion, Antonio Llombart, Sofia Braga, and Javier Cortés from Medica Scientia Innovation Research (MEDSIR) and Hospital Professor Doutor Fernando Fonseca discuss new drugs available for breast cancer (BC) patients with brain metastasis (BM). The better survival of Human Epidermal growth factor receptor-type 2 positive (HER2+) BC patients unmasked the biological predilection of this BC subtype for development of BM. Indeed, central nervous system (CNS) is a frequent metastatic site for HER2+ advanced BC patients. Over the last years, new therapeutic strategies targeting the HER2 protein have been introduced for systemic treatment of HER2+ BC - either tyrosine kinase inhibitors, monoclonal antibodies, or antibody-drug conjugates. Patients with BMs have a poorer outcome, compared with patients without BMs, but their prognosis is also improving with the introduction of new anti HER2+ - targeted therapies. “Our group has been working in the DEBBRAH trial, using trastuzumab deruxtecan for different settings of CNS involvement: stable or progressing BM and/or leptomeningeal carcinomatosis.” The team included patients with HER2+ and HER2-low BC. Activity of trastuzumab-deruxtecan in patients with HER2+ BC and untreated or progressing after local therapy BMs also has been shown in another phase II trial. “The final results are yet to be reported, but so far, we observed intracranial responses in HER2+ BC patients [7].” Read the full editorial: DOI: https://doi.org/10.18632/oncotarget.28435 Correspondence to: Marta Vaz Batista - marta.vaz@hff.min-saude.pt Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28435 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, brain metastasis, HER2+ breast cancer About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

95bFM
More Retreatment Options Needed for Advanced Breast Cancer Patients w/ Breast Cancer Foundation's Adele Gautier: August 28, 2023

95bFM

Play Episode Listen Later Aug 27, 2023


Last Wednesday, Pharmac confirmed it would be replacing treatment Herceptin (brand name for the drug Trastuzumab) with Herzuma, another version of the drug which is equally as effective but at a lower cost. Pharmac has decided not to provide more retreatment opportunities for patients with advanced HER2-positive breast cancer, but Breast Cancer Foundation New Zealand is urging them to reconsider. Rosetta spoke to Adele Gautier, Research and Strategic Programmes Manager for BCFNZ about the decision, and what more needs to be done to increase retreatment options in Aotearoa.

Medscape InDiscussion: Triple-Negative Breast Cancer
How Are ADCs Shifting the Way We're Practicing in TNBC?

Medscape InDiscussion: Triple-Negative Breast Cancer

Play Episode Listen Later Aug 1, 2023 18:03


Join experts Drs Kevin Kalinsky and Aditya Bardia as they discuss utilizing antibody-drug conjugates in clinic. What is currently available? What are the possible side effects? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991254). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4 Introduction to Antibody-drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/ Antibody-drug Conjugates Targeting TROP-2: Clinical Development in Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36302269/ Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview HER2 Status in Breast Cancer: Changes in Guidelines and Complicating Factors for Interpretation https://pubmed.ncbi.nlm.nih.gov/31693827/ Whole-exome Sequencing Identifies Somatic Mutations and Intratumor Heterogeneity in Inflammatory Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34075047/ Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/ Trastuzumab Deruxtecan in Previously Treated HER2-low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/ TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2-metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32223649/ Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/ Scalp Cooling to Prevent Chemotherapy-induced Alopecia https://pubmed.ncbi.nlm.nih.gov/32622629/ First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) https://www.clinicaltrials.gov/search?term=NCT03401385 Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-low Breast Cancer https://ascopost.com/issues/january-25-2023/neoadjuvant-t-dxd-demonstrates-activity-in-phase-ii-study-of-patients-with-her2-low-breast-cancer/ Sacituzumab Govitecan in TNBC (NeoSTAR) https://clinicaltrials.gov/study/NCT04230109 A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) https://www.clinicaltrials.gov/study/NCT05629585 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) https://www.clinicaltrials.gov/study/NCT05633654

ASTRO Journals
Neoadjuvant RT for Locally Advanced Breast Cancer

ASTRO Journals

Play Episode Listen Later Jul 20, 2023 20:48


Editor-in-Chief, Robert Amdur, MD, discusses RT before, rather than after, mastectomy in patients with locally advanced breast cancer being treated with neoadjuvant chemotherapy. The discussion is based on a paper published in the July 2023 issue of PRO titled “Pathologic Complete Response and Oncologic Outcomes in Locally Advanced Breast Cancers Treated With Neoadjuvant Radiation Therapy: An Australian Perspective” (2023, Issue 4, July/August, PMID: 36599393).

Oncology Data Advisor
Additional Advances in PI3K Inhibitor Research & Clinical Trials With Janie Metsker, RN, BSN, CN-BN

Oncology Data Advisor

Play Episode Listen Later May 30, 2023 5:26


Click here to view and claim credit for Managing Toxicities of Novel Breast Cancer Therapies: PI3K Inhibitors, an accredited CME/NCPD/CPE activity by i3 Health: i3health.com/odabc-pi3k. Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia and rash. In this interview from the 48th Annual Oncology Nursing Society (ONS) Congress, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares updated strategies for managing these toxicities in order to provide the best outcomes for patients with breast cancer receiving PI3K inhibitors.

Oncology Peer Review On-The-Go
S1 Ep65: Oncology On-the-Go Podcast: Sacituzumab Govitecan for HR+/HER2– Advanced Breast Cancer

Oncology Peer Review On-The-Go

Play Episode Listen Later Feb 20, 2023 28:34


In a Twitter Spaces edition of the Oncology On-the-Go podcast, Kevin Kalinsky, MD, MS, and Jane Meisel, MD, of Emory Winship Cancer Institute, spoke with CancerNetwork® about how the FDA approval of sacituzumab govitecan-hziy (Trodlevy) for advanced or metastatic hormone receptor–positive, HER2-negative breast cancer will impact the treatment paradigm. Kalinsky, an associate professor in the Department of Hematology and Medical Oncology and director of Breast Medical Oncology, and Meisel, an associate professor in the Department of Hematology and Medical Oncology and in the Department of Gynecology and Obstetrics, discussed data from the phase 3 TROPiCS-02 trial (NCT03901339) that led to the approval and what unmet needs still exist in the space. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

CME in Minutes: Education in Primary Care
Richard Finn, MD - Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes

CME in Minutes: Education in Primary Care

Play Episode Listen Later Feb 15, 2023 16:09


Please visit answersincme.com/WWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC) in the real-world setting. Upon completion of this activity, participants should be better able to: Outline the clinical relevance of real-world evidence in the treatment of HR+/HER2- aBC; Review the latest real-world evidence informing the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- aBC; and Identify patient-centered strategies to integrate real-world evidence into optimized care plans for patients with HR+/HER2- aBC.

Project Oncology®
Exploring the EMERALD Trial: What the Subgroup Analyses of Advanced Breast Cancer Patients Found

Project Oncology®

Play Episode Listen Later Jan 13, 2023


For patients with ER+/HER2- advanced breast cancer, current treatment guidelines recommend the use of endocrine therapy plus a CDK 4/6 inhibitor as a first-line treatment. And while the guidelines recommend sequential endocrine therapy for disease progressions, this progression can lead to ESR1 mutations and resistance to endocrine therapy. Could a novel oral selective estrogen receptor have more efficacy in preventing ESR1 mutations associated with endocrine resistance? That's the exact question the EMERALD trial sought to answer, and what this study found in its subgroup analyses is the focus of this Audio Abstract.

Project Oncology®
Spotlight on SERDs for ER+/HER2- Advanced Breast Cancer: What Clinicians Need to Know

Project Oncology®

Play Episode Listen Later Jan 10, 2023


Host: Jennifer Caudle, DO Guest: Nan Chen, MD Selective estrogen receptor degraders (SERDs) are a novel class of drugs for the treatment of ER+/HER2- advanced breast cancer. So how exactly do they work to treat this type of advanced breast cancer, and what are the findings from recent trials investigating the clinical utility of SERDs? Get the answers to these and other key questions with Dr. Jennifer Caudle and Dr. Nan Chen, Assistant Professor of Medicine at the University of Chicago School of Medicine.

Project Oncology®
Overcoming Challenges in ER+/HER2- Advanced Breast Cancer Care

Project Oncology®

Play Episode Listen Later Jan 10, 2023


Host: Jennifer Caudle, DO Guest: Stephanie Graff, MD Endocrine resistance and toxicities are just a few of the many challenges facing clinicians who treat patients with ER+/HER2- advanced breast cancer. So what strategies can we use to better address these challenges and unmet needs? Joining Dr. Jennifer Caudle to share her approach is Dr. Stephanie Graff, Director of the Breast Oncology Program at Lifespan Cancer Institute in Providence, Rhode Island.

Oncology Data Advisor
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker

Oncology Data Advisor

Play Episode Listen Later Nov 7, 2022 62:29


In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.

At The Beam
S1E7 Locally Advanced Breast Cancer 2 feat. Dr Ryan Morse

At The Beam

Play Episode Listen Later Aug 26, 2022 20:03


Case-based workup and management of another locally advanced breast cancer case. Featuring guest Dr Ryan Morse.

At The Beam
S1E6 Locally Advanced Breast Cancer

At The Beam

Play Episode Listen Later Aug 19, 2022 15:50


Case-based workup and management of locally advanced breast cancer.

PCE
Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

PCE

Play Episode Listen Later Jun 30, 2022 20:56


In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include:An overview of the monarchE study leading to FDA approval of adjuvant abemaciclibKey trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancerManaging adverse events associated with CDK4/6 inhibitorsPromoting adherence to oral therapyPresenter:Julia LaBarbera, MSN, RN, AGACNP-BCNurse PractitionerDivision of Hematology/OncologyDepartment of MedicineUniversity of California, Los AngelesSanta Monica, CaliforniaLink to full program:PCE.is/Onc22

Our MBC Life
S04 E02 - Dr. Timothy Pluard: The Future of MBC Care Is Already Here

Our MBC Life

Play Episode Listen Later Mar 9, 2022 45:59


The future of personalized care for those living with MBC is already here, and it is happening in Kansas City, Missouri. Dr. Timothy  Pluard,  Medical Director of  the Kansas City's  Saint Luke's  Koontz Center for Advanced Breast Cancer  is with us today.  We'll ask him how he and his team create an individualized, completely comprehensive plan for each woman.More info is available on our website www.ourmbclife.org Got something to share? Feedback? Email: ourmbclife@sharecancersupport.org Send us a voice recording via email or through speakpipe on our website.   Follow us on Facebook, Instagram, and Twitter @ourmbclife

TV's Rob is (Un)Woke
The Hard Life of Kendall Jenner and the War on Words

TV's Rob is (Un)Woke

Play Episode Listen Later Jul 12, 2021 116:24


TV's Rob is back again with part two of his conversation with Steven Avery talking all things Star Trek, with a peek into what Steven does for a living and what the future may hold for him. There's a health update on Nikki and the new medication she's on … used to treat ADVANCED BREAST CANCER?!? She doesn't have breast cancer, but damn this stuff knocks her on her ass. A Federal Aviation Administration advisory group is urging the agency to replace words like "airman" and "cockpit" with gender-neutral terms like "aviator" and "flight deck." Kendall Jenner has had a rough life, and we all need to take a moment to reflect on that. She reveals people didn't want to hire her as a model at age 18 because she was already famous from Keeping Up With The Kardashians. If you want to get in on the action and make your mark on the show, go to anchor.fm/tvsrobisunwoke and leave a voice message. I'll play a selection of messages in future episodes. Also, if you want to come on the show and talk about something that's really pissing you off, send me a message on Twitter, @TVsRob_Official Special thanks to Nikki, you can follow her on Twitter @DFWRadioGirlie and Ryoga the special derpy cat, who you can see what he's up to on Twitter as well @CatRyoga If you want to support the show, click on the show page: anchor.fm/tvsrobisunwoke and show your love. Built Bar is giving listeners 10% off at builtbar.com just use the promo code TVSROB --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/tvsrobisunwoke/message Support this podcast: https://anchor.fm/tvsrobisunwoke/support